|
1
|
Nowain A, Bhakta H, Pais S, Kanel G and
Verma S: Gastrointestinal stromal tumors: clinical profile,
pathogenesis, treatment strategies and prognosis. J Gastroenterol
Hepatol. 20:818–824. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Heinrich MC, Rubin BP, Longley BJ, et al:
Biology and genetic aspects of gastrointestinal stromal tumors: KIT
activation and cytogenetic alterations. Hum Pathol. 33:484–495.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vlahovic G and Crawford J: Activation of
tyrosine kinases in cancer. Oncologist. 8:531–538. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Eisenberg BL and Judson I: Surgery and
imatinib in the management of GIST: emerging approaches to adjuvant
and neoadjuvant therapy. Ann Surg Oncol. 11:465–475. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Heinrich MC and Corless CL: Gastric GI
stromal tumors (GISTs): the role of surgery in the era of targeted
therapy. J Surg Oncol. 90:195–207. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Samiian L, Weaver M and Velanovich V:
Evaluation of gastrointestinal stromal tumors for recurrence rates
and patterns of long-term follow-up. Am Surg. 70:187–191.
2004.PubMed/NCBI
|
|
7
|
DeMatteo RP, Heinrich MC, El-Rifai WM and
Demetri G: Clinical management of gastrointestinal stromal tumors:
before and after STI-571. Hum Pathol. 33:466–477. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Demetri GD, vonMehren M, Blanke CD, Vanden
Abbeele AD, Eisenberg B, Roberts PJ, et al: Efficacy and safety of
imatinib mesylate in advanced gastrointestinal stromal tumors. N
Engl J Med. 347:472–480. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bauer S, Duensing A, Demetri GD and
Fletcher JA: KIT oncogenic signaling mechanisms in
imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT
is a crucial survival pathway. Oncogene. 26:7560–7568. 2007.
View Article : Google Scholar
|
|
10
|
Sleijfer S, Wiemer E, Seynaeve C and
Verweij J: Improved insight into resistance mechanisms to imatinib
in gastrointestinal stromal tumors: a basis for novel approaches
and individualization of treatment. Oncologist. 12:719–726. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wardelmann E, Buttner R, Merkelbach-Bruse
S and Schildhaus HU: Mutation analysis of gastrointestinal stromal
tumors: increasing significance for risk assessment and effective
targeted therapy. Virchows Arch. 451:743–749. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tornillo L and Terracciano LM: An update
on molecular genetics of gastrointestinal stromal tumours. J Clin
Pathol. 59:557–563. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sleijfer S, Wiemer E and Verweij J: Drug
insight: gastrointestinal stromal tumors (GIST) - the solid tumor
model for cancer-specific treatment. Nat Clin Pract Oncol.
5:102–111. 2008. View Article : Google Scholar
|
|
14
|
Antonescu CR, Besmer P, Guo T, Arkun K,
Hom G, Koryotowski B, et al: Acquired resistance to imatinib in
gastrointestinal stromal tumor occurs through secondary gene
mutation. Clin Cancer Res. 11:4182–4190. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Debiec-Rychter M, Dumez H, Judson I, Wasag
B, Verweij J, Brown M, Dimitrijevic S, Sciot R, Stul M, Vranck H,
Scurr M, Hagemeijer A, van Glabbeke M and van Oosterom AT; EORTC
Soft Tissue and Bone Sarcoma Group. Use of c-KIT/PDGFRA mutational
analysis to predict the clinical response to imatinib in patients
with advanced gastrointestinal stromal tumours entered on phase I
and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur
J Cancer. 40:689–695. 2004. View Article : Google Scholar
|
|
16
|
Heinrich MC, Corless CL, Blanke CD,
Demetri GD, Joensuu H, Roberts PJ, et al: Molecular correlates of
imatinib resistance in gastrointestinal stromal tumors. J Clin
Oncol. 24:4764–4774. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mahadevan D, Cooke L, Riley C, Swart R,
Simons B, Della Croce K, Wisner L, Iorio M, Shakalya K, Garewal H,
Nagle R and Bearss D: A novel tyrosine kinase switch is a mechanism
of imatinib resistance in gastrointestinal stromal tumors.
Oncogene. 26:3909–3919. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Thao le B, Vu HA, Yasuda K, Taniguchi S,
Yagasaki F, Taguchi T, Watanabe T and Sato Y: Cas-L was
overexpressed in imatinib-resistant gastrointestinal stromal tumor
cells. Cancer Biol Ther. 8:683–688. 2009.PubMed/NCBI
|
|
19
|
Steigen SE and Eide TJ: Trends in
incidence and survival of mesenchymal neoplasm of the digestive
tract within a defined population of northern Norway. APMIS.
114:192–200. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Trent JC and Benjamin RS: New developments
in gastrointestinal stromal tumor. Curr Opin Oncol. 18:386–395.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fletcher CD, Berman JJ, Corless C,
Gorstein F, Lasota J, Longley BJ, Miettinen M, O’Leary TJ, Remotti
H, Rubin BP, Shmookler B, Sobin LH and Weiss SW: Diagnosis of
gastrointestinal stromal tumors: a consensus approach. Int J Surg
Pathol. 10:81–89. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lee JR, Joshi V, Griffin JW Jr, et al:
Gastrointestinal autonomic nerve tumor: immunohistochemical and
molecular identity with gastrointestinal stromal tumor. Am J Surg
Pathol. 25:979–987. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Miettinen M and Lasota J: Gastrointestinal
stromal tumors: review on morphology, molecular pathology,
prognosis, and differential diagnosis. Arch Pathol Lab Med.
130:1466–1478. 2006.PubMed/NCBI
|
|
24
|
Taguchi T, Sonobe H, Toyonaga S, Yamasaki
I, Shuin T, Takano A, Araki K, Akimaru K and Yuri K: Conventional
and molecular cytogenetic characterization of a new human cell
line, GIST-T1, established from gastrointestinal stromal tumor. Lab
Invest. 82:663–665. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tuveson DA, Willis NA, Jacks T, Griffin
JD, Singer S, Fletcher CD, Fletcher JA and Demetri GD: STI571
inactivation of the gastrointestinal stromal tumor c-KIT
oncoprotein: biological and clinical implications. Oncogene.
20:5054–5058. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhu B, Liao G, Liu S, Huang B, Wu S, Zhou
J, Gu H and Zhu H: Characteristics and establishment of cell lines
from human gastrointestinal stromal tumors. Zhong Nan Da Xue Xue
Bao Yi Xue Ban. 35:1138–1144. 2010.PubMed/NCBI
|
|
27
|
Mukaisho K, Miwa K, Totsuka Y, Shimomura
A, Sugihara H, Wakabayashi K and Hattori T: Induction of gastric
GIST in rat and establishment of GIST cell line. Cancer Lett.
231:295–303. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hirota S, Isozaki K, Moriyama Y, Hashimoto
K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M,
Muhammad TG, Matsuzawa Y, Kanakura Y, Shinomura Y and Kitamura Y:
Gain-of-function mutations of c-kit in human stromal tumors.
Science. 279:577–580. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sommer G, Agosti V, Ehlers I, Rossi F,
Corbacioglu S, Farkas J, Moore M, Manova K, Antonescu CR and Besmer
P: Gastrointestinal stromal tumors in a mouse model by targeted
mutation of the kit receptor tyrosine kinase. Proc Natl Acad Sci
USA. 100:6706–6711. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kindblom LG, Remotti HE, Aldenborg F and
Meis-Kindblom JM: Gastrointestinal pacemaker cell tumor (GIPACT):
gastrointestinal stromal tumors show phenotypic characteristics of
the interstitial cells of Cajal. Am J Pathol. 152:1259–1269.
1998.
|
|
31
|
Sircar K, Hewlett BR, Huizinga JD,
Chorneyko K, Berezin I and Riddell RH: Interstitial cells of Cajal
as precursors of gastrointestinal stromal tumors. Am J Surg Pathol.
23:377–389. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Heinrich MC, Corless CL, Duensing A,
McGreevey L, Chen CJ, Joseph N, et al: PDGFRA activating mutations
in gastrointestinal stromal tumors. Science. 299:708–710. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Joensuu H, Roberts PJ, Sarlomo-Rikala M,
Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville
R, Dimitrijevic S, Druker B and Demetri GD: Effect of the tyrosine
kinase inhibitor STI571 in a patient with a metastatic
gastrointestinal stromal tumor. N Engl J Med. 344:1052–1056. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
van Oosterom AT, Judson I, Verweij J,
Stroobants S, Donato di Paola E, Dimitrijevic S, Martens M, Webb A,
Sciot R, Van Glabbeke M, Silberman S and Nielsen OS: Safety and
efficacy of imatinib (STI571) in metastatic gastrointestinal
stromal tumours: a phase I study. Lancet. 358:1421–1423.
2001.PubMed/NCBI
|
|
35
|
Heinrich MC, Corless CL, Demetri GD,
Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den
Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S,
Fletcher CD, Silberman S, Dimitrijevic S and Fletcher JA: Kinase
mutations and imatinib response in patients with metastatic
gastrointestinal stromal tumor. J Clin Oncol. 21:4342–4349. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Blanke CD, Rankin C, Demetri GD, Ryan CW,
von Mehren M, Benjamin RS, Raymond AK, Bramwell VH, Baker LH, Maki
RG, Tanaka M, et al: Phase III randomized, intergroup trial
assessing imatinib mesylate at two dose levels in patients with
unresectable or metastatic gastrointestinal stromal tumors
expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol.
26:626–632. 2008. View Article : Google Scholar
|
|
37
|
Verweij J, Casali PG, Zalcberg J, LeCesne
A, Reichardt P, Blay JY, Issels R, van Oosterom A, Hogendoorn PC,
Van Glabbeke M, Bertulli R, et al: Progression-free survival in
gastrointestinal stromal tumours with high-dose imatinib:
randomised trial. Lancet. 364:1127–1134. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chen LL, Trent JC, Wu EF, Fuller GN,
Ramdas L, Zhang W, Raymond AK, Prieto VG, Oyedeji CO, Hunt KK,
Pollock RE, et al: A missense mutation in KIT kinase domain 1
correlates with imatinib resistance in gastrointestinal stromal
tumors. Cancer Res. 64:5913–5919. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Theou N, Gil S, Devocelle A, Julie C,
Lavergne-Slove A, Beauchet A, Callard P, Farinotti R, Le Cesne A,
Lemoine A, Faivre-Bonhomme L, et al: Multidrug resistance proteins
in gastrointestinal stromal tumors: site-dependent expression and
initial response to imatinib. Clin Cancer Res. 11:7593–7598. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Burger H, Van Tol H, Boersma AW, Brok M,
Wiemer EA, Stoter G and Nooter K: Imatinib mesylate (STI571) is a
substrate for the breast cancer resistance protein (BCRP)/ABCG2
drug pump. Blood. 104:2940–2942. 2004. View Article : Google Scholar : PubMed/NCBI
|
